Suddenly, ACUR patents have become more valuable. What's the likelihood that one of these big Pharma, or even one of the major generic drug companies, who might be losing or can't renew a license to produce the original formuals, might buy ACUR...buy the company...to get the patents? ACUR management has never been good at production or marketing. But the patents are a different subject. The FDA just granted them unique value.